ArticleMayo Clinic proceedings2020
A Case of Coronavirus Disease 2019 Treated With Ciclesonide.
Article in Mayo Clinic proceedings, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Structure-Based Virtual Screening and Functional Validation of Potential Hit Molecules Targeting the SARS-CoV-2 Main Protease.Biomolecules · 2022Article
- Clinical benefits of inhaled ciclesonide for hospitalized patients with COVID-19 infection: a retrospective study.BMC pulmonary medicine · 2022Article
- COVID-19 and corticosteroids: a narrative review.Inflammopharmacology · 2022Review
- Adjuvant Inhaled Corticosteroids in Community-Acquired Pneumonia: A Review Article.Medical sciences (Basel, Switzerland) · 2021Review
- COVID-19: Analysis of Drug Repositioning Practice.Pharmaceutical chemistry journal · 2021Article
- Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses.Advances in experimental medicine and biology · 2021Review
- Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies.Molecular biomedicine · 2021Article
- The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells.Journal of virology · 2020Article
- Article
- Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19.Cellular signalling · 2020Review
- Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a NovelMolecules (Basel, Switzerland) · 2020Article
- Clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise ship.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2020Article
- Is there a role for inhaled ciclesonide in the treatment of COVID-19?Lung India : official organ of Indian Chest SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.